{"transactions":[{"id":1241295,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-27T23:32:38.000Z","date":"2025-02-27","kind":"sale","planned":true,"acquired":false,"shares":100,"price":58.74,"value":5874.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024."}],"balance_after":173756,"source":{"system":"sec-edgar","filing":"0001415889-25-005899","document":"form4-02272025_110233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005899/form4-02272025_110233.xml","form_type":"4"}},{"id":1241294,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-27T23:32:38.000Z","date":"2025-02-27","kind":"sale","planned":true,"acquired":false,"shares":1597,"price":58.252,"value":93028.444,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":173856,"source":{"system":"sec-edgar","filing":"0001415889-25-005899","document":"form4-02272025_110233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005899/form4-02272025_110233.xml","form_type":"4"}},{"id":1241293,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-27T23:32:38.000Z","date":"2025-02-26","kind":"sale","planned":true,"acquired":false,"shares":600,"price":58.648,"value":35188.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":175453,"source":{"system":"sec-edgar","filing":"0001415889-25-005899","document":"form4-02272025_110233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005899/form4-02272025_110233.xml","form_type":"4"}},{"id":1241292,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-27T23:32:38.000Z","date":"2025-02-26","kind":"sale","planned":true,"acquired":false,"shares":9400,"price":58.091,"value":546055.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":176053,"source":{"system":"sec-edgar","filing":"0001415889-25-005899","document":"form4-02272025_110233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005899/form4-02272025_110233.xml","form_type":"4"}},{"id":1241291,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-27T23:32:38.000Z","date":"2025-02-25","kind":"sale","planned":true,"acquired":false,"shares":700,"price":58.67,"value":41069.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":185453,"source":{"system":"sec-edgar","filing":"0001415889-25-005899","document":"form4-02272025_110233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005899/form4-02272025_110233.xml","form_type":"4"}},{"id":1241290,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-27T23:32:38.000Z","date":"2025-02-25","kind":"sale","planned":true,"acquired":false,"shares":9300,"price":58.007,"value":539465.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":186153,"source":{"system":"sec-edgar","filing":"0001415889-25-005899","document":"form4-02272025_110233.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005899/form4-02272025_110233.xml","form_type":"4"}},{"id":1250107,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-02-24T22:11:03.000Z","date":"2025-02-23","kind":"exercise","planned":false,"acquired":false,"shares":4747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":14238,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4747},"source":{"system":"sec-edgar","filing":"0001415889-25-005311","document":"form4-02242025_100257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005311/form4-02242025_100257.xml","form_type":"4"}},{"id":1250106,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-24T22:11:03.000Z","date":"2025-02-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":2410,"price":57.75,"value":139177.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 2,410 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":195453,"source":{"system":"sec-edgar","filing":"0001415889-25-005311","document":"form4-02242025_100257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005311/form4-02242025_100257.xml","form_type":"4"}},{"id":1250105,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-24T22:11:03.000Z","date":"2025-02-23","kind":"exercise","planned":false,"acquired":true,"shares":4747,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":197863,"source":{"system":"sec-edgar","filing":"0001415889-25-005311","document":"form4-02242025_100257.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005311/form4-02242025_100257.xml","form_type":"4"}},{"id":1253556,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-02-21T23:52:10.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":11230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":11230,"derivative":{"exercise_price":0,"exercise_date":"2026-02-20","underlying":"Common Stock","underlying_shares":11230},"source":{"system":"sec-edgar","filing":"0001415889-25-005177","document":"form4-02212025_110206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005177/form4-02212025_110206.xml","form_type":"4"}},{"id":1253555,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2025-02-21T23:52:10.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":11902,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":11902,"derivative":{"exercise_price":57.44,"exercise_date":"2026-02-20","expiration_date":"2035-02-20","underlying":"Common Stock","underlying_shares":11902},"source":{"system":"sec-edgar","filing":"0001415889-25-005177","document":"form4-02212025_110206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925005177/form4-02212025_110206.xml","form_type":"4"}},{"id":1264541,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-02-18T23:42:31.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":false,"shares":4263,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":8526,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4263},"source":{"system":"sec-edgar","filing":"0001415889-25-004509","document":"form4-02182025_110228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004509/form4-02182025_110228.xml","form_type":"4"}},{"id":1264540,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-02-18T23:42:31.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":false,"shares":6112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":6112,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6112},"source":{"system":"sec-edgar","filing":"0001415889-25-004509","document":"form4-02182025_110228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004509/form4-02182025_110228.xml","form_type":"4"}},{"id":1264539,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2025-02-18T23:42:31.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":false,"shares":20891,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":20891},"source":{"system":"sec-edgar","filing":"0001415889-25-004509","document":"form4-02182025_110228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004509/form4-02182025_110228.xml","form_type":"4"}},{"id":1264538,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-02-18T23:42:31.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":false,"shares":3386,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3386},"source":{"system":"sec-edgar","filing":"0001415889-25-004509","document":"form4-02182025_110228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004509/form4-02182025_110228.xml","form_type":"4"}},{"id":1264537,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:42:31.000Z","date":"2025-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":2164,"price":58.29,"value":126139.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The reported disposition of 2,164 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":193116,"source":{"system":"sec-edgar","filing":"0001415889-25-004509","document":"form4-02182025_110228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004509/form4-02182025_110228.xml","form_type":"4"}},{"id":1264536,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:42:31.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":true,"shares":4263,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":195280,"source":{"system":"sec-edgar","filing":"0001415889-25-004509","document":"form4-02182025_110228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004509/form4-02182025_110228.xml","form_type":"4"}},{"id":1264535,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:42:31.000Z","date":"2025-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":3103,"price":58.29,"value":180873.87,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The reported disposition of 3,103 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":191017,"source":{"system":"sec-edgar","filing":"0001415889-25-004509","document":"form4-02182025_110228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004509/form4-02182025_110228.xml","form_type":"4"}},{"id":1264534,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:42:31.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":true,"shares":6112,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":194120,"source":{"system":"sec-edgar","filing":"0001415889-25-004509","document":"form4-02182025_110228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004509/form4-02182025_110228.xml","form_type":"4"}},{"id":1264533,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:42:31.000Z","date":"2025-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":8721,"price":58.29,"value":508347.09,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported disposition of 8,721 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":188008,"source":{"system":"sec-edgar","filing":"0001415889-25-004509","document":"form4-02182025_110228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004509/form4-02182025_110228.xml","form_type":"4"}},{"id":1264532,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:42:31.000Z","date":"2025-02-16","kind":"exercise","planned":false,"acquired":true,"shares":20891,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":196729,"source":{"system":"sec-edgar","filing":"0001415889-25-004509","document":"form4-02182025_110228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004509/form4-02182025_110228.xml","form_type":"4"}},{"id":1264531,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:42:31.000Z","date":"2025-02-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":1304,"price":58.29,"value":76010.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported disposition of 1,304 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":175838,"source":{"system":"sec-edgar","filing":"0001415889-25-004509","document":"form4-02182025_110228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004509/form4-02182025_110228.xml","form_type":"4"}},{"id":1264530,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T23:42:31.000Z","date":"2025-02-15","kind":"exercise","planned":false,"acquired":true,"shares":3386,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":177142,"source":{"system":"sec-edgar","filing":"0001415889-25-004509","document":"form4-02182025_110228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004509/form4-02182025_110228.xml","form_type":"4"}},{"id":1267871,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2025-02-14T23:12:02.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":20342,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":20342,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":20342},"source":{"system":"sec-edgar","filing":"0001415889-25-004243","document":"form4-02142025_110258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004243/form4-02142025_110258.xml","form_type":"4"}},{"id":1267870,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Performance Stock Unit","published_at":"2025-02-14T23:12:02.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":4921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 23, 2024 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":4921,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4921},"source":{"system":"sec-edgar","filing":"0001415889-25-004243","document":"form4-02142025_110258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004243/form4-02142025_110258.xml","form_type":"4"}},{"id":1267869,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2025-02-14T23:12:02.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":4177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2023 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2023 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":6547,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4177},"source":{"system":"sec-edgar","filing":"0001415889-25-004243","document":"form4-02142025_110258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004243/form4-02142025_110258.xml","form_type":"4"}},{"id":1267868,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Performance Stock Units","published_at":"2025-02-14T23:12:02.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":7262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2022 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The Issuer awarded the reporting person performance-based vesting stock units (\"PSUs\") on February 16, 2022 that included a performance measurement period ending December 31, 2024.  This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period.  The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date."}],"balance_after":20891,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7262},"source":{"system":"sec-edgar","filing":"0001415889-25-004243","document":"form4-02142025_110258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588925004243/form4-02142025_110258.xml","form_type":"4"}},{"id":1386102,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-10-16T22:53:48.000Z","date":"2024-10-16","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":26608,"derivative":{"exercise_price":19.98,"expiration_date":"2030-02-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-025233","document":"form4-10162024_101045.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924025233/form4-10162024_101045.xml","form_type":"4"}},{"id":1386101,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-10-16T22:53:48.000Z","date":"2024-10-15","kind":"exercise","planned":true,"acquired":false,"shares":4491,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":36608,"derivative":{"exercise_price":19.98,"expiration_date":"2030-02-10","underlying":"Common Stock","underlying_shares":4491},"source":{"system":"sec-edgar","filing":"0001415889-24-025233","document":"form4-10162024_101045.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924025233/form4-10162024_101045.xml","form_type":"4"}},{"id":1386100,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-10-16T22:53:48.000Z","date":"2024-10-15","kind":"exercise","planned":true,"acquired":false,"shares":5509,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":6352,"derivative":{"exercise_price":16.65,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":5509},"source":{"system":"sec-edgar","filing":"0001415889-24-025233","document":"form4-10162024_101045.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924025233/form4-10162024_101045.xml","form_type":"4"}},{"id":1386099,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-10-16T22:53:48.000Z","date":"2024-10-16","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":53.259,"value":532590.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $52.88 to $53.60. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":173756,"source":{"system":"sec-edgar","filing":"0001415889-24-025233","document":"form4-10162024_101045.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924025233/form4-10162024_101045.xml","form_type":"4"}},{"id":1386098,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-10-16T22:53:48.000Z","date":"2024-10-16","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":19.98,"value":199800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":183756,"source":{"system":"sec-edgar","filing":"0001415889-24-025233","document":"form4-10162024_101045.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924025233/form4-10162024_101045.xml","form_type":"4"}},{"id":1386097,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-10-16T22:53:48.000Z","date":"2024-10-15","kind":"sale","planned":true,"acquired":false,"shares":77,"price":54.245,"value":4176.865,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":173756,"source":{"system":"sec-edgar","filing":"0001415889-24-025233","document":"form4-10162024_101045.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924025233/form4-10162024_101045.xml","form_type":"4"}},{"id":1386096,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-10-16T22:53:48.000Z","date":"2024-10-15","kind":"sale","planned":true,"acquired":false,"shares":9923,"price":53.743,"value":533291.789,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $53.24 to $54.22. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":173833,"source":{"system":"sec-edgar","filing":"0001415889-24-025233","document":"form4-10162024_101045.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924025233/form4-10162024_101045.xml","form_type":"4"}},{"id":1386095,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-10-16T22:53:48.000Z","date":"2024-10-15","kind":"exercise","planned":true,"acquired":true,"shares":4491,"price":19.98,"value":89730.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":183756,"source":{"system":"sec-edgar","filing":"0001415889-24-025233","document":"form4-10162024_101045.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924025233/form4-10162024_101045.xml","form_type":"4"}},{"id":1386094,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-10-16T22:53:48.000Z","date":"2024-10-15","kind":"exercise","planned":true,"acquired":true,"shares":5509,"price":16.65,"value":91724.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":179265,"source":{"system":"sec-edgar","filing":"0001415889-24-025233","document":"form4-10162024_101045.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924025233/form4-10162024_101045.xml","form_type":"4"}},{"id":1403936,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-09-18T22:49:57.000Z","date":"2024-09-18","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":11861,"derivative":{"exercise_price":16.65,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-023657","document":"form4-09182024_100954.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924023657/form4-09182024_100954.xml","form_type":"4"}},{"id":1403935,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-09-18T22:49:57.000Z","date":"2024-09-17","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":21861,"derivative":{"exercise_price":16.65,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-023657","document":"form4-09182024_100954.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924023657/form4-09182024_100954.xml","form_type":"4"}},{"id":1403934,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-09-18T22:49:57.000Z","date":"2024-09-18","kind":"sale","planned":true,"acquired":false,"shares":2037,"price":62.581,"value":127477.497,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $62.41 to $62.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":173756,"source":{"system":"sec-edgar","filing":"0001415889-24-023657","document":"form4-09182024_100954.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924023657/form4-09182024_100954.xml","form_type":"4"}},{"id":1403933,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-09-18T22:49:57.000Z","date":"2024-09-18","kind":"sale","planned":true,"acquired":false,"shares":7963,"price":61.891,"value":492838.033,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $61.40 to $62.395. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":175793,"source":{"system":"sec-edgar","filing":"0001415889-24-023657","document":"form4-09182024_100954.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924023657/form4-09182024_100954.xml","form_type":"4"}},{"id":1403932,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-09-18T22:49:57.000Z","date":"2024-09-18","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":16.65,"value":166500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":183756,"source":{"system":"sec-edgar","filing":"0001415889-24-023657","document":"form4-09182024_100954.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924023657/form4-09182024_100954.xml","form_type":"4"}},{"id":1403931,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-09-18T22:49:57.000Z","date":"2024-09-17","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":62.878,"value":628780.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $62.585 to $63.275. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":173756,"source":{"system":"sec-edgar","filing":"0001415889-24-023657","document":"form4-09182024_100954.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924023657/form4-09182024_100954.xml","form_type":"4"}},{"id":1403930,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-09-18T22:49:57.000Z","date":"2024-09-17","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":16.65,"value":166500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":183756,"source":{"system":"sec-edgar","filing":"0001415889-24-023657","document":"form4-09182024_100954.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924023657/form4-09182024_100954.xml","form_type":"4"}},{"id":1422214,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-08-27T23:49:52.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":false,"shares":5580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":18.41,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":5580},"source":{"system":"sec-edgar","filing":"0001415889-24-022363","document":"form4-08272024_110848.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924022363/form4-08272024_110848.xml","form_type":"4"}},{"id":1422213,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-27T23:49:52.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":true,"shares":5580,"price":18.41,"value":102727.8,"ownership":{"direct":true},"balance_after":173756,"source":{"system":"sec-edgar","filing":"0001415889-24-022363","document":"form4-08272024_110848.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924022363/form4-08272024_110848.xml","form_type":"4"}},{"id":1426704,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-08-21T22:03:29.000Z","date":"2024-08-21","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":31861,"derivative":{"exercise_price":16.65,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-021850","document":"form4-08212024_100827.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924021850/form4-08212024_100827.xml","form_type":"4"}},{"id":1426703,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-08-21T22:03:29.000Z","date":"2024-08-20","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":41861,"derivative":{"exercise_price":16.65,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-021850","document":"form4-08212024_100827.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924021850/form4-08212024_100827.xml","form_type":"4"}},{"id":1426702,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-21T22:03:29.000Z","date":"2024-08-21","kind":"sale","planned":true,"acquired":false,"shares":100,"price":62.34,"value":6234.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":168176,"source":{"system":"sec-edgar","filing":"0001415889-24-021850","document":"form4-08212024_100827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924021850/form4-08212024_100827.xml","form_type":"4"}},{"id":1426701,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-21T22:03:29.000Z","date":"2024-08-21","kind":"sale","planned":true,"acquired":false,"shares":9900,"price":61.741,"value":611235.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $61.325 to $62.32. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":168276,"source":{"system":"sec-edgar","filing":"0001415889-24-021850","document":"form4-08212024_100827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924021850/form4-08212024_100827.xml","form_type":"4"}},{"id":1426700,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-21T22:03:29.000Z","date":"2024-08-21","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":16.65,"value":166500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":178176,"source":{"system":"sec-edgar","filing":"0001415889-24-021850","document":"form4-08212024_100827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924021850/form4-08212024_100827.xml","form_type":"4"}},{"id":1426699,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-21T22:03:29.000Z","date":"2024-08-20","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":61.055,"value":610550.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $60.65 to $61.51. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":168176,"source":{"system":"sec-edgar","filing":"0001415889-24-021850","document":"form4-08212024_100827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924021850/form4-08212024_100827.xml","form_type":"4"}},{"id":1426698,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-21T22:03:29.000Z","date":"2024-08-20","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":16.65,"value":166500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":178176,"source":{"system":"sec-edgar","filing":"0001415889-24-021850","document":"form4-08212024_100827.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924021850/form4-08212024_100827.xml","form_type":"4"}},{"id":1449514,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-07-24T21:48:14.000Z","date":"2024-07-24","kind":"exercise","planned":true,"acquired":false,"shares":8285,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":51861,"derivative":{"exercise_price":16.65,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-020055","document":"form4-07242024_090711.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924020055/form4-07242024_090711.xml","form_type":"4"}},{"id":1449513,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-07-24T21:48:14.000Z","date":"2024-07-24","kind":"exercise","planned":true,"acquired":false,"shares":1715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":8.11,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-020055","document":"form4-07242024_090711.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924020055/form4-07242024_090711.xml","form_type":"4"}},{"id":1449512,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-07-24T21:48:14.000Z","date":"2024-07-23","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":1715,"derivative":{"exercise_price":8.11,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-020055","document":"form4-07242024_090711.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924020055/form4-07242024_090711.xml","form_type":"4"}},{"id":1449511,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-24T21:48:14.000Z","date":"2024-07-24","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":55.115,"value":551150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $54.89 to $55.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":168176,"source":{"system":"sec-edgar","filing":"0001415889-24-020055","document":"form4-07242024_090711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924020055/form4-07242024_090711.xml","form_type":"4"}},{"id":1449510,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-24T21:48:14.000Z","date":"2024-07-24","kind":"exercise","planned":true,"acquired":true,"shares":8285,"price":16.65,"value":137945.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":178176,"source":{"system":"sec-edgar","filing":"0001415889-24-020055","document":"form4-07242024_090711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924020055/form4-07242024_090711.xml","form_type":"4"}},{"id":1449509,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-24T21:48:14.000Z","date":"2024-07-24","kind":"exercise","planned":true,"acquired":true,"shares":1715,"price":8.11,"value":13908.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":169891,"source":{"system":"sec-edgar","filing":"0001415889-24-020055","document":"form4-07242024_090711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924020055/form4-07242024_090711.xml","form_type":"4"}},{"id":1449508,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-24T21:48:14.000Z","date":"2024-07-23","kind":"sale","planned":true,"acquired":false,"shares":5291,"price":55.265,"value":292407.115,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $55.08 to $55.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":168176,"source":{"system":"sec-edgar","filing":"0001415889-24-020055","document":"form4-07242024_090711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924020055/form4-07242024_090711.xml","form_type":"4"}},{"id":1449507,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-24T21:48:14.000Z","date":"2024-07-23","kind":"sale","planned":true,"acquired":false,"shares":4709,"price":54.463,"value":256466.267,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $54.05 to $54.97. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":173467,"source":{"system":"sec-edgar","filing":"0001415889-24-020055","document":"form4-07242024_090711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924020055/form4-07242024_090711.xml","form_type":"4"}},{"id":1449506,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-07-24T21:48:14.000Z","date":"2024-07-23","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":8.11,"value":81100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":178176,"source":{"system":"sec-edgar","filing":"0001415889-24-020055","document":"form4-07242024_090711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924020055/form4-07242024_090711.xml","form_type":"4"}},{"id":1473556,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-06-20T20:17:09.000Z","date":"2024-06-18","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":11715,"derivative":{"exercise_price":8.11,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-017625","document":"form4-06202024_080605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924017625/form4-06202024_080605.xml","form_type":"4"}},{"id":1473555,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-06-20T20:17:09.000Z","date":"2024-06-18","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":49.426,"value":494260.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $49.00 to $49.74. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":168176,"source":{"system":"sec-edgar","filing":"0001415889-24-017625","document":"form4-06202024_080605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924017625/form4-06202024_080605.xml","form_type":"4"}},{"id":1473554,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-06-20T20:17:09.000Z","date":"2024-06-18","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":8.11,"value":81100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":178176,"source":{"system":"sec-edgar","filing":"0001415889-24-017625","document":"form4-06202024_080605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924017625/form4-06202024_080605.xml","form_type":"4"}},{"id":1505866,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-05-22T21:24:16.000Z","date":"2024-05-22","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":21715,"derivative":{"exercise_price":8.11,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-014123","document":"form4-05222024_090507.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924014123/form4-05222024_090507.xml","form_type":"4"}},{"id":1505865,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-05-22T21:24:16.000Z","date":"2024-05-21","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":31715,"derivative":{"exercise_price":8.11,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-014123","document":"form4-05222024_090507.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924014123/form4-05222024_090507.xml","form_type":"4"}},{"id":1505864,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-05-22T21:24:16.000Z","date":"2024-05-22","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":45.384,"value":453840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $45.20 to $45.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":168176,"source":{"system":"sec-edgar","filing":"0001415889-24-014123","document":"form4-05222024_090507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924014123/form4-05222024_090507.xml","form_type":"4"}},{"id":1505863,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-05-22T21:24:16.000Z","date":"2024-05-22","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":8.11,"value":81100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":178176,"source":{"system":"sec-edgar","filing":"0001415889-24-014123","document":"form4-05222024_090507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924014123/form4-05222024_090507.xml","form_type":"4"}},{"id":1505862,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-05-22T21:24:16.000Z","date":"2024-05-21","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":45.164,"value":451640.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $44.785 to $45.455. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":168176,"source":{"system":"sec-edgar","filing":"0001415889-24-014123","document":"form4-05222024_090507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924014123/form4-05222024_090507.xml","form_type":"4"}},{"id":1505861,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-05-22T21:24:16.000Z","date":"2024-05-21","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":8.11,"value":81100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":178176,"source":{"system":"sec-edgar","filing":"0001415889-24-014123","document":"form4-05222024_090507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924014123/form4-05222024_090507.xml","form_type":"4"}},{"id":1540240,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-04-17T23:22:45.000Z","date":"2024-04-17","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":41715,"derivative":{"exercise_price":8.11,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-011058","document":"form4-04172024_110437.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924011058/form4-04172024_110437.xml","form_type":"4"}},{"id":1540239,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-04-17T23:22:45.000Z","date":"2024-04-16","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":51715,"derivative":{"exercise_price":8.11,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-011058","document":"form4-04172024_110437.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924011058/form4-04172024_110437.xml","form_type":"4"}},{"id":1540238,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-04-17T23:22:45.000Z","date":"2024-04-17","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":38.489,"value":384890.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $38.275 to $38.785. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":168176,"source":{"system":"sec-edgar","filing":"0001415889-24-011058","document":"form4-04172024_110437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924011058/form4-04172024_110437.xml","form_type":"4"}},{"id":1540237,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-04-17T23:22:45.000Z","date":"2024-04-17","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":8.11,"value":81100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":178176,"source":{"system":"sec-edgar","filing":"0001415889-24-011058","document":"form4-04172024_110437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924011058/form4-04172024_110437.xml","form_type":"4"}},{"id":1540236,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-04-17T23:22:45.000Z","date":"2024-04-16","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":38.35,"value":383500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":168176,"source":{"system":"sec-edgar","filing":"0001415889-24-011058","document":"form4-04172024_110437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924011058/form4-04172024_110437.xml","form_type":"4"}},{"id":1540235,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-04-17T23:22:45.000Z","date":"2024-04-16","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":8.11,"value":81100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":178176,"source":{"system":"sec-edgar","filing":"0001415889-24-011058","document":"form4-04172024_110437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924011058/form4-04172024_110437.xml","form_type":"4"}},{"id":1560840,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-26T23:38:51.000Z","date":"2024-03-26","kind":"exercise","planned":false,"acquired":false,"shares":2890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":61715,"derivative":{"exercise_price":8.11,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":2890},"source":{"system":"sec-edgar","filing":"0001415889-24-009158","document":"form4-03262024_110343.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924009158/form4-03262024_110343.xml","form_type":"4"}},{"id":1560839,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-26T23:38:51.000Z","date":"2024-03-26","kind":"exercise","planned":false,"acquired":false,"shares":292,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on July 2, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":16.78,"expiration_date":"2028-07-02","underlying":"Common Stock","underlying_shares":292},"source":{"system":"sec-edgar","filing":"0001415889-24-009158","document":"form4-03262024_110343.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924009158/form4-03262024_110343.xml","form_type":"4"}},{"id":1560838,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-26T23:38:51.000Z","date":"2024-03-26","kind":"exercise","planned":false,"acquired":false,"shares":8436,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":8436},"source":{"system":"sec-edgar","filing":"0001415889-24-009158","document":"form4-03262024_110343.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924009158/form4-03262024_110343.xml","form_type":"4"}},{"id":1560837,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-26T23:38:51.000Z","date":"2024-03-26","kind":"exercise","planned":false,"acquired":true,"shares":2890,"price":8.11,"value":23437.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents an acquisition of 2,890 shares by the Reporting Person pursuant to a cash exercise and hold transaction."}],"balance_after":168176,"source":{"system":"sec-edgar","filing":"0001415889-24-009158","document":"form4-03262024_110343.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924009158/form4-03262024_110343.xml","form_type":"4"}},{"id":1560836,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-26T23:38:51.000Z","date":"2024-03-26","kind":"exercise","planned":false,"acquired":true,"shares":292,"price":16.78,"value":4899.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents an acquisition of 292 shares by the Reporting Person pursuant to a cash exercise and hold transaction."}],"balance_after":165286,"source":{"system":"sec-edgar","filing":"0001415889-24-009158","document":"form4-03262024_110343.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924009158/form4-03262024_110343.xml","form_type":"4"}},{"id":1560835,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-26T23:38:51.000Z","date":"2024-03-26","kind":"exercise","planned":false,"acquired":true,"shares":8436,"price":12.07,"value":101822.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an acquisition of 8,436 shares by the Reporting Person pursuant to a cash exercise and hold transaction."}],"balance_after":164994,"source":{"system":"sec-edgar","filing":"0001415889-24-009158","document":"form4-03262024_110343.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924009158/form4-03262024_110343.xml","form_type":"4"}},{"id":1579151,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-13T21:22:18.000Z","date":"2024-03-13","kind":"exercise","planned":true,"acquired":false,"shares":3551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":64605,"derivative":{"exercise_price":8.11,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":3551},"source":{"system":"sec-edgar","filing":"0001415889-24-007825","document":"form4-03132024_090313.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924007825/form4-03132024_090313.xml","form_type":"4"}},{"id":1579150,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-13T21:22:18.000Z","date":"2024-03-13","kind":"exercise","planned":true,"acquired":false,"shares":6449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":8436,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":6449},"source":{"system":"sec-edgar","filing":"0001415889-24-007825","document":"form4-03132024_090313.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924007825/form4-03132024_090313.xml","form_type":"4"}},{"id":1579149,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-03-13T21:22:18.000Z","date":"2024-03-12","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":14885,"derivative":{"exercise_price":12.07,"expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-007825","document":"form4-03132024_090313.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924007825/form4-03132024_090313.xml","form_type":"4"}},{"id":1579148,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-13T21:22:18.000Z","date":"2024-03-13","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":42.273,"value":422730.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.00 to $42.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":156558,"source":{"system":"sec-edgar","filing":"0001415889-24-007825","document":"form4-03132024_090313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924007825/form4-03132024_090313.xml","form_type":"4"}},{"id":1579147,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-13T21:22:18.000Z","date":"2024-03-13","kind":"exercise","planned":true,"acquired":true,"shares":3551,"price":8.11,"value":28798.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":166558,"source":{"system":"sec-edgar","filing":"0001415889-24-007825","document":"form4-03132024_090313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924007825/form4-03132024_090313.xml","form_type":"4"}},{"id":1579146,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-13T21:22:18.000Z","date":"2024-03-13","kind":"exercise","planned":true,"acquired":true,"shares":6449,"price":12.07,"value":77839.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":163007,"source":{"system":"sec-edgar","filing":"0001415889-24-007825","document":"form4-03132024_090313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924007825/form4-03132024_090313.xml","form_type":"4"}},{"id":1579145,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-13T21:22:18.000Z","date":"2024-03-12","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":41.637,"value":416370.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $41.26 to $42.035. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":156558,"source":{"system":"sec-edgar","filing":"0001415889-24-007825","document":"form4-03132024_090313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924007825/form4-03132024_090313.xml","form_type":"4"}},{"id":1579144,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-13T21:22:18.000Z","date":"2024-03-12","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":12.07,"value":120700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":166558,"source":{"system":"sec-edgar","filing":"0001415889-24-007825","document":"form4-03132024_090313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924007825/form4-03132024_090313.xml","form_type":"4"}},{"id":1612818,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-28T23:49:54.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":false,"shares":7471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter."}],"balance_after":68156,"derivative":{"exercise_price":8.11,"expiration_date":"2026-02-03","underlying":"Common Stock","underlying_shares":7471},"source":{"system":"sec-edgar","filing":"0001415889-24-005756","document":"form4-02282024_110246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924005756/form4-02282024_110246.xml","form_type":"4"}},{"id":1612817,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-28T23:49:54.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":7471,"price":39.542,"value":295418.282,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.37 to $39.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":156558,"source":{"system":"sec-edgar","filing":"0001415889-24-005756","document":"form4-02282024_110246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924005756/form4-02282024_110246.xml","form_type":"4"}},{"id":1612816,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-28T23:49:54.000Z","date":"2024-02-28","kind":"exercise","planned":true,"acquired":true,"shares":7471,"price":8.11,"value":60589.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."}],"balance_after":164029,"source":{"system":"sec-edgar","filing":"0001415889-24-005756","document":"form4-02282024_110246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924005756/form4-02282024_110246.xml","form_type":"4"}},{"id":1612815,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-28T23:49:54.000Z","date":"2024-02-28","kind":"sale","planned":true,"acquired":false,"shares":2529,"price":39.559,"value":100044.711,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.40 to $39.82. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":156558,"source":{"system":"sec-edgar","filing":"0001415889-24-005756","document":"form4-02282024_110246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924005756/form4-02282024_110246.xml","form_type":"4"}},{"id":1612814,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-28T23:49:54.000Z","date":"2024-02-27","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":39.946,"value":399460.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.757 to $40.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":159087,"source":{"system":"sec-edgar","filing":"0001415889-24-005756","document":"form4-02282024_110246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924005756/form4-02282024_110246.xml","form_type":"4"}},{"id":1616468,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2024-02-27T22:12:10.000Z","date":"2024-02-23","kind":"grant","planned":false,"acquired":true,"shares":18985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":18985,"derivative":{"exercise_price":0,"exercise_date":"2025-02-23","underlying":"Common Stock","underlying_shares":18985},"source":{"system":"sec-edgar","filing":"0001415889-24-005547","document":"form4-02272024_100206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924005547/form4-02272024_100206.xml","form_type":"4"}},{"id":1616467,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Option to Purchase Common Stock","published_at":"2024-02-27T22:12:10.000Z","date":"2024-02-23","kind":"grant","planned":false,"acquired":true,"shares":19674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":19674,"derivative":{"exercise_price":40.56,"exercise_date":"2025-02-23","expiration_date":"2034-02-23","underlying":"Common Stock","underlying_shares":19674},"source":{"system":"sec-edgar","filing":"0001415889-24-005547","document":"form4-02272024_100206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924005547/form4-02272024_100206.xml","form_type":"4"}},{"id":1634622,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2024-02-20T23:59:00.000Z","date":"2024-02-16","kind":"exercise","planned":false,"acquired":false,"shares":4264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":12789,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4264},"source":{"system":"sec-edgar","filing":"0001415889-24-004477","document":"form4-02202024_110252.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004477/form4-02202024_110252.xml","form_type":"4"}},{"id":1634621,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2024-02-20T23:59:00.000Z","date":"2024-02-16","kind":"exercise","planned":false,"acquired":false,"shares":6112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer."}],"balance_after":12224,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6112},"source":{"system":"sec-edgar","filing":"0001415889-24-004477","document":"form4-02202024_110252.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004477/form4-02202024_110252.xml","form_type":"4"}},{"id":1634620,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":82745,"kind":"person","name":"LaBarre Michael J.","position":1,"cik":"0001507174","reported_name":"LaBarre Michael J.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CHIEF TECHNICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-20T23:59:00.000Z","date":"2024-02-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":2160,"price":36.1,"value":77976.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported disposition of 2,160 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations."}],"balance_after":169087,"source":{"system":"sec-edgar","filing":"0001415889-24-004477","document":"form4-02202024_110252.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000141588924004477/form4-02202024_110252.xml","form_type":"4"}}],"next_cursor":"2024-02-20T23:59:00.000000Z,1634620"}